Recent from talks
Dilip Shanghvi
Knowledge base stats:
Talk channels stats:
Members stats:
Dilip Shanghvi
Dilip Shanghvi (born 1 October 1955) is an Indian billionaire businessman. Shanghvi is the founder of Sun Pharmaceuticals, a pharmaceutical company. The Government of India awarded him the civilian honor of the Padma Shri in 2016. India Today magazine ranked him 8th in India's most powerful people of 2017 list. According to Forbes, as of May 2025, Shanghvi is the fifth richest person in India with an estimated net worth of US$28.9 billion. He was the recipient of the EY Entrepreneur of the Year Award, India, 2005.
Dilip Shanghvi was born in 1955 in a Jain family from Gujarat, India. He was raised in Kolkata, where his father ran a small wholesale business trading generic medicines. Shanghvi studied at J. J. Ajmera High School. and later earned a Bachelor of Commerce degree from the University of Calcutta. During his early years, he helped his father manage the family’s pharmaceutical trading business, gaining firsthand experience of the industry. This background inspired him to start manufacturing his own medicines rather than just selling other companies’ products.
After working in his father’s pharmaceutical distribution business in Kolkata, Dilip Shanghvi decided to start manufacturing his own medicines. In 1983, he founded Sun Pharmaceutical Industries with a small loan from his father, focusing initially on psychiatric drugs. The company began with a single manufacturing facility in Vapi, Gujarat.
Sun Pharma steadily expanded its product range and market reach over the next decade. By 1993, profits had grown significantly, allowing Shanghvi to invest in dedicated research and development facilities.
Under his leadership, Sun Pharma became known for its strategy of acquiring other companies to fuel growth. The most notable was the $4 billion acquisition of Ranbaxy Laboratories in 2014, which made Sun Pharma India’s largest pharmaceutical company and among the top global generic drug makers.
Despite facing regulatory challenges and a drop in profits between 2014 and 2018, Shanghvi steered the company through recovery. By 2023, Sun Pharma reported profits exceeding ₹8,000 crore, with strong growth in its specialty medicines segment.
In the FY 26, Sun Pharma's net profit stood at Rs 11,479 crores, and revenues were Rs 58,220 crores.
Shanghvi has also overseen international acquisitions, including US-based Ocular Technologies in 2016 and Concert Pharmaceuticals in 2023, expanding Sun Pharma’s global footprint in specialty drugs.
Hub AI
Dilip Shanghvi AI simulator
(@Dilip Shanghvi_simulator)
Dilip Shanghvi
Dilip Shanghvi (born 1 October 1955) is an Indian billionaire businessman. Shanghvi is the founder of Sun Pharmaceuticals, a pharmaceutical company. The Government of India awarded him the civilian honor of the Padma Shri in 2016. India Today magazine ranked him 8th in India's most powerful people of 2017 list. According to Forbes, as of May 2025, Shanghvi is the fifth richest person in India with an estimated net worth of US$28.9 billion. He was the recipient of the EY Entrepreneur of the Year Award, India, 2005.
Dilip Shanghvi was born in 1955 in a Jain family from Gujarat, India. He was raised in Kolkata, where his father ran a small wholesale business trading generic medicines. Shanghvi studied at J. J. Ajmera High School. and later earned a Bachelor of Commerce degree from the University of Calcutta. During his early years, he helped his father manage the family’s pharmaceutical trading business, gaining firsthand experience of the industry. This background inspired him to start manufacturing his own medicines rather than just selling other companies’ products.
After working in his father’s pharmaceutical distribution business in Kolkata, Dilip Shanghvi decided to start manufacturing his own medicines. In 1983, he founded Sun Pharmaceutical Industries with a small loan from his father, focusing initially on psychiatric drugs. The company began with a single manufacturing facility in Vapi, Gujarat.
Sun Pharma steadily expanded its product range and market reach over the next decade. By 1993, profits had grown significantly, allowing Shanghvi to invest in dedicated research and development facilities.
Under his leadership, Sun Pharma became known for its strategy of acquiring other companies to fuel growth. The most notable was the $4 billion acquisition of Ranbaxy Laboratories in 2014, which made Sun Pharma India’s largest pharmaceutical company and among the top global generic drug makers.
Despite facing regulatory challenges and a drop in profits between 2014 and 2018, Shanghvi steered the company through recovery. By 2023, Sun Pharma reported profits exceeding ₹8,000 crore, with strong growth in its specialty medicines segment.
In the FY 26, Sun Pharma's net profit stood at Rs 11,479 crores, and revenues were Rs 58,220 crores.
Shanghvi has also overseen international acquisitions, including US-based Ocular Technologies in 2016 and Concert Pharmaceuticals in 2023, expanding Sun Pharma’s global footprint in specialty drugs.